# A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Source: https://onco.cc/trials/nct07218926/  
OnCo record `nct07218926` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing IDRX-42 in gastrointestinal stromal tumour, now recruiting.

## Summary

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumours After Imatinib Therapy is a phase 3 interventional study registered as NCT07218926, led by GlaxoSmithKline, and recruiting on the registry. Official title: A Phase 3, Randomised, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumours (GIST) After Imatinib Therapy (StrateGIST 3). Planned enrolment is 450 participants (estimated). The study started in 2025-12-03 and primary completion is expected in 2028-05-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: StrateGIST 3
- Tags: ctgov-ingest
- Registry id: NCT07218926
- Phase: 3
- Setting: A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)
- Sponsor: GlaxoSmithKline
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT07218926: https://clinicaltrials.gov/study/NCT07218926

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/), [Imatinib-resistant GIST](https://onco.cc/cancers/gist-imatinib-resistant/)
- drugs: [IDRX-42](https://onco.cc/drugs/idrx-42/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07218926.json